Extend LymphAdenectomy for Intrahepatic Cholangiocarcinoma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Intrahepatic CholangiocarcinomaExtend LymphAdenectomy - Procedure
Eligibility
18 - 80
All Sexes
What conditions do you have?
Select

Study Summary

This trial is studying the standardization of lymph node dissection in ICC.

Eligible Conditions
  • Intrahepatic Cholangiocarcinoma

Treatment Effectiveness

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: 3 years after surgery

3 years after surgery
3-year Overall survival (OS)
5 years after surgery
5-year Overall survival (OS)
Disease free survival (DFS)
Month 2
Rate of Postoperative Complications (PC)

Trial Safety

Trial Design

2 Treatment Groups

Regional LymphAdenectomy
1 of 2
Extend LymphAdenectomy
1 of 2

Active Control

Experimental Treatment

168 Total Participants · 2 Treatment Groups

Primary Treatment: Extend LymphAdenectomy · No Placebo Group · N/A

Extend LymphAdenectomy
Procedure
Experimental Group · 1 Intervention: Extend LymphAdenectomy · Intervention Types: Procedure
Regional LymphAdenectomyNoIntervention Group · 1 Intervention: Regional LymphAdenectomy · Intervention Types:

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 3 years after surgery

Who is running the clinical trial?

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityLead Sponsor
669 Previous Clinical Trials
1,674,411 Total Patients Enrolled
1 Trials studying Intrahepatic Cholangiocarcinoma
9 Patients Enrolled for Intrahepatic Cholangiocarcinoma

Eligibility Criteria

Age 18 - 80 · All Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a Child-Turcotte-Pugh score of A or B.
You have a residual liver volume of 30% or more
You have no obvious lymph node metastasis in preoperative imaging; or negative intraoperative lymph node biopsy.
References